24.03.2021     08:00–19:30

ePoster self study
ePoster self study


ePoster self study
ePoster self study

P 164 Thermostabilization of a broad-spectrum RG1-VLP HPV vaccine candidate
Bettina Huber (Vienna/AT)

P 165 Three HSV1 mutants lead to attenuated phenotypes and induce immunity with protective effect against viral infection in animal models
Xingli Xu (Kunming/CN)

P 166 Germline targeting and epitope focusing HIV-1 Env immunogens with potential for viral and non-viral membrane display
Jasmin Gille (Regensburg/DE)

P 168 Understanding the influence of individual and systemic factors on vaccination take-up in European citizens aged 55 or more
Olympia E. Anastasiou (Essen/DE)

P 169 Structure of expression framework for additional antigens matters - in vitro comparison of Measles virus-derived recombinant vaccine candidates
Samada Muraleedharan (Langen/DE)

P 170 Establishment of a sensitive luciferase-based assay for detection of infectious alphaviruses.
Christin Schmidt (Langen/DE)

P 171 A chicken cell line stably expressing virus like particles and comparison of two promoters
Nina Wolfrum (Zürich/CH)

P 172 Generation of a stable trivalent MVA against hemorrhagic fever viruses
Martina Billmeier (Regensburg/DE)

P 173 Influenza Virus-based Vector Vaccines against Tick-Borne Encephalitis Virus (TBEV)
Jana Beicht (Hannover/DE)

P 174 Safe and highly effective two-in-one replicon-and-VLP minispike vaccine for COVID-19
Alexandru A Hennrich (München/DE)

P 175 Improving the HIV Env antibody response by intrastructural help from tuberculosis subunit vaccine induced CD4+ T cells
Stephan Klessing (Erlangen/DE)

P 176 Generation of Sars-CoV2- and ZIKV-specific monoclonal antibodies by in vitro immunization using cell-permeable virus-like particles as antigen carrier
Younes Husria (Langen/DE)

P 177 Design and immunogenicity evaluation of Adeno-associated virus (AAV) – vectors containing SARS-CoV-2 receptor-binding domain (S-RBD)
Sandra Stelzer (Berlin/DE)

P 178 A systemic DNA prime followed by mucosal vaccination with adenoviral vectors induces potent mucosal and systemic immune responses against SARS-CoV-2
Dennis Lapuente (Erlangen/DE)

P 179 Co-administration of a protein vaccine together with DNA or poxvirus priming immunizations accelerates the development of HIV-specific humoral immune responses
Benedikt Asbach (Regensburg/DE)

P 181 Inactivated full-virus vaccines protect against pigeon-type Rotavirus A (RVA) and "young pigeon disease" (YPD)
Dennis Rubbenstroth (Greifswald - Insel Riems/DE)

P 182 Coronacept – a potent immunoadhesin against SARS-CoV-2
Hadas Cohen-Dvashi (Rehovot/IL)

P 183 Human cytomegalovirus (HCMV)-based T cell vaccine for severe acute respiratory syndrome corona virus 2 (SARS-CoV-2)
Mohammed O. Abdelaziz (Berlin/DE)

P 184 High-throughput foci counting of viral titer and antibody neutralization assays using the Celigo Image Cytometer for developing novel cross-reactive influenza vaccine
Jordan Bell (Lawrence, MA/US)